• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 31, 2017

View Archived Issues

Earnings

Seattle Genetics Inc., of Bothell, Wash., reported second quarter revenues of $108.2 million, including $74.3 million in net sales of Adcetris (brentuximab vedotin) in the U.S. and Canada, compared to revenues of $95.4 million in the second quarter of 2016. Read More

In the clinic

Idorsia Ltd., of Allschwil, Switzerland, reported that the phase II program of its dual orexin receptor antagonist (DORA), known as ACT-541468, met its primary endpoint in insomnia, using zolpidem as an active comparator. Read More

Other news to note

Tiziana Life Sciences plc, of London, said preclinical data for foralumab (NI-0401), an oral anti-CD3 monoclonal antibody, was published in Clinical Immunology. Read More

Study finds potential new treatment for Zika virus

A potent new anti-Zika virus peptide that appears to be safe and reduces viral levels in pregnant mice and their fetuses, has been identified in a Chinese study published in the July 25, 2017, edition of Nature Communications. Read More

K-sunshine act aims to clean up corruption in S. Korean pharma sector

HONG KONG – After the kickback scandal involving Novartis AG, South Korean authorities are determined to root out corruption from the country's pharmaceutical sector. (See BioWorld Today, Sept. 6, 2016.) Read More

Australian patients get help via amended access plan for unapproved drugs, devices

PERTH, Australia – Patients in Australia will now be able to get unapproved drugs through their doctors more quickly since Australia amended its drug and device regulations earlier this year. Read More

Lawmakers creating some answers to high drug prices

While recognizing that the bipartisan Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act is not a silver bullet that will bring down all drug prices, U.S. officials and several experts gave the bill high marks last week during a House Judiciary subcommittee on antitrust concerns and the FDA drug approval process. Read More

Nantcell bets up to $365M on Cytrx's aldoxorubicin

Nantcell Inc., the Patrick Soon-Shiong-backed company built in part with funds from the blockbuster albumin-bound chemotherapy Abraxane (nab-paclitaxel), has exclusively licensed Cytrx Corp.'s aldoxorubicin, another albumin-bound therapy, to incorporate into the treatment of multiple tumor types in combination with other immuno-oncology and cell-based therapies. Read More

Astrazeneca says Merck instigated Lynparza; MYSTIC fizzle not conclusive factor

The fog began to dissipate at least somewhat late last week regarding the reasons behind – and the potential immuno-oncology (IO) fallout from – Astrazeneca plc's phase III blowup with the MYSTIC trial in non-small-cell lung cancer (NSCLC), news of which came just as the pharma giant made public its $8.5 billion deal with Merck & Co. Inc. around the oral poly ADP ribose polymerase (PARP) inhibitor Lynparza (olaparib). Read More

Heplisav gets thumbs-up; FDA Adcom recommends stringent postmarketing study to evaluate 'spurious' CV data

A cardiovascular signal that earned a second complete response letter (CRL) for Dynavax Technologies Corp.'s hepatitis B vaccine, Heplisav, was determined by members of the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) largely to be a "spurious" finding that should be investigated more fully in a required postmarketing study. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • Incurix describes new c-Myc inhibitors

    BioWorld Science
    Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe